Ultragenyx Pharmaceutical Inc (RARE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$15.57-9.27%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RARE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | 730.0 | 673.0 | 560.2 | 434.0 | 363.3 | 351.4 | 271.0 | 103.7 | 51.5 | 2.6 | 0.1 | — | — |
| Total Revenues | — | — | — | — | — | — | — | — | — | 2.6 | — | — | — |
| Cost of Revenues | — | — | — | — | — | — | — | — | 1.1 | — | — | — | — |
| Operating Expenses & Income | |||||||||||||
| Selling, General & Admin | 361.0 | 349.0 | 321.6 | 310.0 | 278.1 | 220.0 | 182.9 | 161.5 | 127.7 | 99.9 | — | — | — |
| R&D Expenses | 711.0 | 750.0 | 697.9 | 648.0 | 705.8 | 497.2 | 412.1 | 357.4 | 294.0 | 231.6 | 183.2 | 114.7 | 46.0 |
| Operating Income | (467.0) | (535.0) | (536.0) | (569.0) | (648.9) | (381.7) | (330.1) | (424.2) | (371.4) | (328.9) | (248.0) | (147.7) | (56.8) |
| Earnings from Continuing Operations | |||||||||||||
| Interest & Investment Income | 20.0 | 25.0 | 36.5 | 27.0 | 11.1 | 1.9 | 7.0 | 13.2 | 9.5 | 4.1 | 3.8 | 2.3 | 0.6 |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | — | — | — | 2.2 | 2.1 | (3.0) |
| EBT, Incl. Unusual Items | (530.0) | (571.0) | (567.6) | (609.0) | (701.7) | (453.0) | (185.4) | (399.4) | (197.1) | (318.3) | (245.8) | — | — |
| Income Tax Expense | (6.0) | 4.0 | 1.6 | (2.0) | 5.7 | 1.0 | 1.2 | 3.3 | 0.5 | (16.2) | 0.0 | 0.0 | — |
| Net Income | |||||||||||||
| Net Income | (524.0) | (575.0) | (569.2) | (607.0) | (707.4) | (454.0) | (186.6) | (402.7) | (197.6) | (302.1) | (245.9) | (145.6) | (59.8) |
| Per Share | |||||||||||||
| Basic EPS | (5.13) | (5.83) | (6.29) | (8.25) | (10.12) | (6.70) | (3.07) | — | — | — | — | — | — |
| Diluted EPS | (5.13) | (5.83) | (6.29) | (8.25) | (10.12) | (6.70) | (3.07) | — | — | — | — | — | — |
| Revenue per Share | 7.15 | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividend per Share | — | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 |
| Basic Weighted Avg Shares | 102.1 | 98.6 | 90.5 | 73.5 | 69.9 | 67.8 | 60.8 | — | — | — | — | 36.8 | 28.8 |
| Diluted Weighted Avg Shares | 102.1 | 98.6 | 90.5 | 73.5 | 69.9 | 67.8 | 60.8 | — | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | (500.0) | (500.4) | (543.0) | (630.7) | (368.5) | (317.9) | (415.6) | (351.8) | (323.1) | (244.6) | (146.4) | (56.1) |
| EBIT | (467.0) | (535.0) | (536.0) | (569.0) | (648.9) | (381.7) | (330.1) | (424.2) | (371.4) | (328.9) | (248.0) | (147.7) | (56.8) |
| Effective Tax Rate | 1.1% | — | — | 0.3% | -0.8% | -0.2% | -0.7% | -0.8% | -0.3% | 5.1% | -0.0% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.